A Case of Small Cell Lung Cancer Treated with Concurrent Chemoradiotherapy with Carboplatin plus Etoposide in a Hemodialysis Patient

Takeshi Terashima, Eri Iwami, Shotaro Chubachi, Shinnosuke Ikemura, Takahiro Nakajima, Tatsu Matsuzaki, Hiroshi Aoyagi

Research output: Contribution to journalArticle

Abstract

In recent years, many patients have had to undergo hemodialysis due to chronic renal failure. In addition, the number of hemodialysis patients in whom lung cancer is discovered is increasing. However, a standard chemoradiotherapy regimen for limited-disease small-cell lung cancer patients undergoing maintenance hemodialysis has not yet been established. We administered concurrent chemoradiotherapy using carboplatin 300 mg/m2 (day 1) plus etoposide 50 mg/m2 (day 1, 3). A partial response was achieved after 4 courses of chemotherapy and 68 Gy of radiotherapy. The major toxicities were hematological toxicities; they included grade 4 thrombocytopenia, grade 3 anemia, and neutropenia.

Original languageEnglish
Pages (from-to)99-101
Number of pages3
JournalGan to kagaku ryoho. Cancer & chemotherapy
Volume43
Issue number1
Publication statusPublished - 2016 Jan 1
Externally publishedYes

Fingerprint

Carboplatin
Small Cell Lung Carcinoma
Chemoradiotherapy
Etoposide
Renal Dialysis
Neutropenia
Chronic Kidney Failure
Anemia
Lung Neoplasms
Radiotherapy
Maintenance
Drug Therapy

ASJC Scopus subject areas

  • Medicine(all)

Cite this

A Case of Small Cell Lung Cancer Treated with Concurrent Chemoradiotherapy with Carboplatin plus Etoposide in a Hemodialysis Patient. / Terashima, Takeshi; Iwami, Eri; Chubachi, Shotaro; Ikemura, Shinnosuke; Nakajima, Takahiro; Matsuzaki, Tatsu; Aoyagi, Hiroshi.

In: Gan to kagaku ryoho. Cancer & chemotherapy, Vol. 43, No. 1, 01.01.2016, p. 99-101.

Research output: Contribution to journalArticle

@article{bdf56fe4c81349568c0b7a22a6525b0c,
title = "A Case of Small Cell Lung Cancer Treated with Concurrent Chemoradiotherapy with Carboplatin plus Etoposide in a Hemodialysis Patient",
abstract = "In recent years, many patients have had to undergo hemodialysis due to chronic renal failure. In addition, the number of hemodialysis patients in whom lung cancer is discovered is increasing. However, a standard chemoradiotherapy regimen for limited-disease small-cell lung cancer patients undergoing maintenance hemodialysis has not yet been established. We administered concurrent chemoradiotherapy using carboplatin 300 mg/m2 (day 1) plus etoposide 50 mg/m2 (day 1, 3). A partial response was achieved after 4 courses of chemotherapy and 68 Gy of radiotherapy. The major toxicities were hematological toxicities; they included grade 4 thrombocytopenia, grade 3 anemia, and neutropenia.",
author = "Takeshi Terashima and Eri Iwami and Shotaro Chubachi and Shinnosuke Ikemura and Takahiro Nakajima and Tatsu Matsuzaki and Hiroshi Aoyagi",
year = "2016",
month = "1",
day = "1",
language = "English",
volume = "43",
pages = "99--101",
journal = "Japanese Journal of Cancer and Chemotherapy",
issn = "0385-0684",
publisher = "Japanese Journal of Cancer and Chemotherapy Publishers Inc.",
number = "1",

}

TY - JOUR

T1 - A Case of Small Cell Lung Cancer Treated with Concurrent Chemoradiotherapy with Carboplatin plus Etoposide in a Hemodialysis Patient

AU - Terashima, Takeshi

AU - Iwami, Eri

AU - Chubachi, Shotaro

AU - Ikemura, Shinnosuke

AU - Nakajima, Takahiro

AU - Matsuzaki, Tatsu

AU - Aoyagi, Hiroshi

PY - 2016/1/1

Y1 - 2016/1/1

N2 - In recent years, many patients have had to undergo hemodialysis due to chronic renal failure. In addition, the number of hemodialysis patients in whom lung cancer is discovered is increasing. However, a standard chemoradiotherapy regimen for limited-disease small-cell lung cancer patients undergoing maintenance hemodialysis has not yet been established. We administered concurrent chemoradiotherapy using carboplatin 300 mg/m2 (day 1) plus etoposide 50 mg/m2 (day 1, 3). A partial response was achieved after 4 courses of chemotherapy and 68 Gy of radiotherapy. The major toxicities were hematological toxicities; they included grade 4 thrombocytopenia, grade 3 anemia, and neutropenia.

AB - In recent years, many patients have had to undergo hemodialysis due to chronic renal failure. In addition, the number of hemodialysis patients in whom lung cancer is discovered is increasing. However, a standard chemoradiotherapy regimen for limited-disease small-cell lung cancer patients undergoing maintenance hemodialysis has not yet been established. We administered concurrent chemoradiotherapy using carboplatin 300 mg/m2 (day 1) plus etoposide 50 mg/m2 (day 1, 3). A partial response was achieved after 4 courses of chemotherapy and 68 Gy of radiotherapy. The major toxicities were hematological toxicities; they included grade 4 thrombocytopenia, grade 3 anemia, and neutropenia.

UR - http://www.scopus.com/inward/record.url?scp=84965091951&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84965091951&partnerID=8YFLogxK

M3 - Article

C2 - 26809534

AN - SCOPUS:84965091951

VL - 43

SP - 99

EP - 101

JO - Japanese Journal of Cancer and Chemotherapy

JF - Japanese Journal of Cancer and Chemotherapy

SN - 0385-0684

IS - 1

ER -